AC Immune (NASDAQ:ACIU) Issues Earnings Results, Beats Estimates By $0.02 EPS

AC Immune (NASDAQ:ACIU) released its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02, FiscalAI reports. AC Immune had a negative return on equity of 97.79% and a negative net margin of 181.38%. The business had revenue of $3.88 million for the quarter, compared to analysts’ expectations of $1.62 million.

AC Immune Trading Up 4.2%

ACIU stock traded up $0.09 on Friday, hitting $2.20. The company had a trading volume of 73,287 shares, compared to its average volume of 265,694. AC Immune has a 12-month low of $2.02 and a 12-month high of $3.90. The stock’s 50-day simple moving average is $2.55 and its 200 day simple moving average is $2.70. The stock has a market cap of $223.69 million, a price-to-earnings ratio of -4.37 and a beta of 1.64.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ACIU shares. Zacks Research cut AC Immune from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 28th. HC Wainwright initiated coverage on AC Immune in a research report on Thursday. They set a “strong-buy” rating on the stock. Weiss Ratings upgraded AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Finally, BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.50.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.